Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director · President and CEO | February 01, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date February 01, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2034-01-31 | Direct | 500,000 |
Reported balance
After 2024-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2024 Filed Feb 2, 2024 21:10 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0000950170-24-010491 · ownership.xml · derivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:29 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 14,391 | $4.37 | $62,888.67 |
DisclosureSEC source: 0000950170-24-003648 · ownership.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,248 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020 and 10,808 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:21 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001209191-23-007513 · doc4.xml · derivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:09 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 45,907 | $5.24 | $240,552.68 |
DisclosureSEC source: 0001209191-23-002979 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,639 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 7, 2019, 16,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, and 10,808 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $5.11 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,246 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · derivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,246 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F7 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 620 | $33.28 | $20,633.60 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · nonDerivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,546 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $33.03 to $33.67 per share. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 2,703 | $32.61 | $88,144.83 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,166 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $32.02 to $33.01 per share. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 2,923 | $31.33 | $91,577.59 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,869 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $30.99 to $31.74 per share. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 6,246 | $2.70 | $16,864.20 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · derivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,246 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F7 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 19,171 | $33.07 | $633,984.97 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,546 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $32.83 to $33.33 per share. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 10,829 | $32.54 | $352,375.66 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,717 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $31.82 to $32.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 22:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 30,000 | $2.70 | $81,000.00 |
DisclosureSEC source: 0001209191-22-043143 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $2.70 Strike: $2.70 | $27,000.00 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · derivative · entry 10 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,246 Underlying: Common Stock · 10,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F8 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 838 | $35.15 | $29,455.70 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · nonDerivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,546 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F7 · price: Represents the weighted average sale price of the shares sold from $35.04 to $35.29 per share. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 9,162 | $34.54 | $316,455.48 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · nonDerivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,384 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F6 · price: Represents the weighted average sale price of the shares sold from $34.04 to $35.03 per share. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 10,000 | $2.70 | $27,000.00 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $2.70 Strike: $2.70 | $81,000.00 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · derivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,246 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F8 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,003 | $37.90 | $38,013.70 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,546 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold from $37.70 to $38.38 per share. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 2,220 | $36.70 | $81,474.00 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,549 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold from $36.29 to $37.08 per share. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,062 | $35.73 | $145,135.26 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,769 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $35.29 to $36.25 per share. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 22,715 | $34.57 | $785,257.55 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,831 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $34.22 to $35.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 30,000 | $2.70 | $81,000.00 |
DisclosureSEC source: 0001209191-22-025515 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:09 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 289,403 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000899243-22-003426 · doc4.xml · derivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,403 Underlying: Common Stock · 289,403 shares Expires 2032-01-24 F1 · derivative.exercise_date: The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 21:36 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $2.70 Strike: $2.70 | $27,000.00 |
DisclosureSEC source: 0001209191-22-004606 · doc4.xml · derivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,446 Underlying: Common Stock · 10,000 shares Expires 2026-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 21:36 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 10,000 | $38.02 | $380,200.00 |
DisclosureSEC source: 0001209191-22-004606 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,546 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 21:36 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 10,000 | $2.70 | $27,000.00 |
DisclosureSEC source: 0001209191-22-004606 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| January 21, 2022 Filed Feb 4, 2022 22:59 UTC Amendment | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0000899243-22-004871 · doc4a.xml · derivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,246 Underlying: Common Stock · 10,000 shares Expires 2026-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · derivative.exercise_date: This stock option is fully vested. F4 · balance_after: Corrected ending balance of this option which includes 36,800 shares that are vested and outstanding pursuant to a second option grant issued on January 12, 2016. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 21:36 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $2.73 Strike: $2.73 | $81,900.00 |
DisclosureSEC source: 0001209191-22-004606 · doc4.xml · derivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 21:36 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 30,000 | $40.21 | $1,206,300.00 |
DisclosureSEC source: 0001209191-22-004606 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,546 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 21:36 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 30,000 | $2.73 | $81,900.00 |
DisclosureSEC source: 0001209191-22-004606 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| January 20, 2022 Filed Feb 4, 2022 22:59 UTC Amendment | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0000899243-22-004871 · doc4a.xml · derivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,246 Underlying: Common Stock · 30,000 shares Expires 2026-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Corrected option price. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · derivative.exercise_date: This stock option is fully vested. F4 · balance_after: Corrected ending balance of this option which includes 36,800 shares that are vested and outstanding pursuant to a second option grant issued on January 12, 2016. Read SEC document |
| January 20, 2022 Filed Feb 4, 2022 22:59 UTC Amendment | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 30,000 | $2.70 | $81,000.00 |
DisclosureSEC source: 0000899243-22-004871 · doc4a.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F2 · price: Corrected option price. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:09 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,519 | $49.07 | $221,747.33 |
DisclosureSEC source: 0001209191-22-003174 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,546 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 10,807 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.70 to $49.40 per share. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:09 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 10,047 | $48.50 | $487,279.50 |
DisclosureSEC source: 0001209191-22-003174 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,065 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 10,807 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.70 to $48.69 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 101 | $47.72 | $4,819.72 |
DisclosureSEC source: 0001209191-22-003054 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,112 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 20,894 | $47.17 | $985,569.98 |
DisclosureSEC source: 0001209191-22-003054 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,213 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $46.72 to $47.67 per share. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 13,161 | $46.36 | $610,143.96 |
DisclosureSEC source: 0001209191-22-003054 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,107 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $45.72 to $46.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 22:45 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 86,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066168 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,268 F2 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:45 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-21-066168 · doc4.xml · derivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,446 Underlying: Common Stock · 20,000 shares Expires 2026-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:45 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 20,000 | $54.27 | $1,085,400.00 |
DisclosureSEC source: 0001209191-21-066168 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:45 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 20,000 | $2.70 | $54,000.00 |
DisclosureSEC source: 0001209191-21-066168 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,154 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · derivative · entry 11 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,446 Underlying: Common Stock · 15,154 shares Expires 2026-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,846 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · derivative · entry 10 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,846 shares Expires 2025-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · derivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 30,000 | $58.88 | $1,766,400.00 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · nonDerivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 15,154 | $2.70 | $40,915.80 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 4,846 | $4.84 | $23,454.64 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 10,000 | $2.73 | $27,300.00 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001209191-21-061485 · doc4.xml · derivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.